Tag: Cellectis
Cellectis: Cécile Chartier joins the Board of Directors
By Alexandra Saintpierre Published on 07/13/2023 at 2:04 p.m. (Boursier.com) — Cellectis announces that during its meeting…
Cellectis will present a poster on its BALLI-01 clinical trial in Frankfurt
By Alexandra Saintpierre Published on 05/11/2023 at 8:08 p.m. (Boursier.com) — The biotechnology company Cellectis announced the…
Cellectis Announces First Patient Dosing in Europe with In-house Manufactured UCART22 Product Candidate
By Hector Chaunu Published on 04/12/2023 at 07:21 Photo credit © Cellectis – Ramon Martinez (Boursier.com) — Cellectis…
Cellectis: the terms of the ADS offer are known – 02/03/2023 at 12:10
(CercleFinance.com) – Cellectis unveiled yesterday evening the terms of its capital increase project of 20.2 million dollars via the marketing of new American Depositary Shares (ADS). In a press release,…
Cellectis: the terms of the ADS offer are known
(CercleFinance.com) – Cellectis unveiled yesterday evening the terms of its capital increase project of 20.2 million dollars via the marketing of new American Depositary Shares (ADS). In a press release,…
Cellectis: modification of Cytovia’s convertible rating – 01/23/2023 at 11:31
(CercleFinance.com) – Cellectis announced on Friday evening that it had modified the convertible note by $20 million as part of the collaboration agreement with its partner Cytovia Therapeutics. The biotechnology…
Cellectis: Calyxt and Cibus sign a merger agreement
Through Jean-Noel Legalland Published on 01/17/2023 at 1:33 p.m. (Boursier.com) —…
Cellectis obtains a loan of 40 million euros from the European Investment Bank – 29/12/2022 at 08:42
(AOF) – Cellectis, a clinical-stage biotechnology company that uses its pioneering genome-editing technology to develop innovative therapies for the treatment of serious diseases, today announces the signing of a credit…
Cellectis: financing contract with the EIB
(CercleFinance.com) – Cellectis announces the signature of a credit agreement for a total amount of 40 million euros with the European Investment Bank (EIB), divided into three tranches A, B…
Cellectis: UCART22 has been administered to a first patient for the treatment of acute lymphoblastic leukemia
(Boursier.com) — Cellectis a clinical-stage biotechnology company that uses its pioneering TALEN genome-editing technology to develop innovative therapies for the treatment of serious diseases, today announces that its in-house manufactured…
Cellectis: first patient treated in leukemia – 23/12/2022 at 11:40
(CercleFinance.com) – Cellectis announced on Friday that its product candidate UCART22 had been administered to a first patient as part of a study dedicated to the treatment of acute lymphoblastic…
Cellectis: first patient treated in leukemia
(CercleFinance.com) – Cellectis announced on Friday that its product candidate UCART22 had been administered to a first patient as part of a study dedicated to the treatment of acute lymphoblastic…